Investment for Advanced Therapies
Cell, Gene & Immunotherapy

EUROPE’S MOST COMPREHENSIVE INVESTMENT COVERAGE ALONGSIDE ISCT 2017

CMS CAMERON MCKENNA OFFICES, CANNON PLACE, CITY OF LONDON

Genghis Lloyd-Harris, Partner, Abingworth
Dmitry Kuzmin, Managing Partner, 4BIO Capital
Dr Markus Goebel, Managing Director, Novartis Venture Fund
Simon Goldman, Investment Manager, UCL Technology Fund, Albion Ventures
Dr Sven Kili, VP & Head of Gene Therapy Development, GlaxoSmithKline
Dr David Sourdive, EVP Technical Operations, Cellectis
Timothy Moore, EVP of Technical Operations, Kite Pharma
Dr Nick Crabb, Programme Director, Scientific Affairs, NICE

180+ DELEGATES
85% SENIOR DIRECTOR
50+ INVESTORS
GLOBAL BIOTECH COMPANIES (EARLY TO LATE STAGE)
INVITED INVESTORS INCLUDE:

- 4Bio Capital Partners
- Abingworth
- Advent Life Sciences
- Albion Ventures
- Arix Bioscience
- AXA Framlington
- Bellevue
- Cambridge Innovation Capital
- EdRIP
- Enso Ventures
- Epidarex Capital
- Hadean Ventures
- HBM Partners
- Healthcor
- Henderson Volantis Capital
- Ignite Capital Partners
- Imperial Innovations
- Investec
- Kreos Capital
- Lansdowne
- Legal & General
- Longbow Capital
- Lundbeck Fund
- Medicxi Ventures
- MS Ventures
- NBGI Ventures
- New Science Global Healthcare Fund
- Omega Funds
- Orbimed
- Polar Capital
- Proteus Venture Partners
- Rosetta Capital
- Seroba Life Sciences
- Seventure Partners
- Sixth Element Capital
- Sofinnova Partners
- SPARK Impact Ltd
- SR-One
- SV Life Sciences Managers
- Syncona Partners
- The Wellcome Trust
- Versant Ventures
- Woodford Investment

THE SUMMIT

Taking place during ISCT 2017, this will be the C-Level meeting place for heavyweight investors, analysts, biotechs, venture partners and industry experts who are driving the industry forward. Don’t miss your chance to shape the future and put your company on the map!

CONFIRMED SPEAKERS

- Genghis Lloyd-Harris, Partner, Abingworth
- Dr Thomas Taapken, CFO, Medigene
- Dr Sven Kili, VP & Head of Gene Therapy Development, GlaxoSmithKline
- Dr David Sourdive, EVP Technical Operations, Cellectis
- Dr Stephane Boissel, CEO, TxCell
- Dr Magda Papadaki, Head of Manufacturing Innovation, The Association of the British Pharmaceutical Industry
- Dr David Venables, CEO, Synpromics
- Dr Robert Jan Lamers, CEO, Arthrogen
- Timothy Moore, EVP of Technical Operations, Kite Pharma
- Ferran Prat, VP Strategic Industry Ventures, MD Anderson Cancer Center
- Dr John Beadle, CEO, PsiOxus Therapeutics
- Dr Marc Turner, Medical Director, SNBTS
- Dr Nick Crabb, Programme Director, Scientific Affairs, NICE
- Dmitry Kuzmin, Managing Partner, 4BIO Capital
- Dr Hakan Goker, Senior Investment Director, Merck Ventures
- Dr Markus Goebel, Managing Director, Novartis Venture Fund
- Robin Davison, Healthcare Analyst, New Science Global Healthcare Fund
- Simon Goldman, Investment Manager, UCL Technology Fund, Albion Ventures
- Tay Salimullah, Global Pricing & Market Access Director, Cell & Gene Therapies, Novartis Pharma AG

THE ADVANCED THERAPIES INVESTMENT REPORT

To help fuel investment and speed innovation, Phacilitate are commissioning an independent report that will be sent to an audience of investors and potential venture partners with the aim of promoting hard facts, data and in depth case studies demonstrating how and where investors can make money from the sector.

Working with an advisory board of industry leaders, analysts and KOLs, this comprehensive report will clarify the market outlook with an investment roadmap to 2020 and showcase the most promising companies and investment opportunities.

Through sponsoring, you can be integrally involved in the development of this industry leading report, raising your profile amongst an incredibly influential audience whilst positioning your company as a market leader and a business that is driving the growth of cell, gene and immunotherapy.

PARTICIPATING BIOTECH COMPANIES

More information available at: www.advancedtherapiesinvestment.com
WEDNESDAY 3RD MAY 2017

AGENDA

Assessing the clinical and commercial landscape for ATMPs - A Pharma/Biotech perspective

8.30: INVESTOR PERSPECTIVE: The opportunities of cell & gene therapy and why now?

- What is the current funding environment directed to novel drug R&D and how does this change at different phases of development?
- Identifying robust science with a clear pathway to a differentiated approved product in a busy marketplace. How can you determine risk, reward and revenue?
- What is the decision-making process when investing in compelling technologies that have commercial potential?

Genghis Lloyd-Harris, Partner, Abingworth
Ferran Pratt, VP Strategic Industry Ventures, MD Anderson Cancer Center
Dmitry Kuzmin, Managing Partner, 4BIO Capital

9.15: BIOTECH PERSPECTIVE: The opportunities of cell & gene therapy and why now?

- What are the current funding environment directed to novel drug R&D and how does this change at different phases of development?
- Identifying robust science with a clear pathway to a differentiated approved product in a busy marketplace. How can you determine risk, reward and revenue?
- What is the decision-making process when investing in compelling technologies that have commercial potential?

Dr Thomas Taapken, CFO, Medigene
Dr John Beadle, CEO, PsiOxus Therapeutics
Dr Stephane Boissel, CEO, TxCell

10.00 FIRESIDE CHATS: Evaluation of the clinical success for Ex-Vivo Gene Therapies

- How encouraging progress has been made in the clinical use of gene-based therapy for a variety of diseases, including severe combined immunodeficiency disease (SCID-X1), adenosine deaminase-severe combined immunodeficiency (ADA-SCID) and Leber’s congenital amaurosis (LCA).
- How CAR-T therapeutic success in hematologic cancers can provide a framework for investigational treatment of solid tumour malignancies.

Dr Sven Kili, VP & Head of Gene Therapy Development, GSK
Dr Rick Morgan, VP, Immunotherapy, bluebird bio

10.30 EVENT PARTNER PRESENTATION: Supporting clinical progress with technology platforms

10.45: Refreshments & Networking

11.15: Bringing the benefits of advanced therapeutics to patients

- Healthcare Regulatory perspective: Insight from the MHRA and the EMA’s Committee on Advanced Therapies (CAT)
- What scientific evidence will be necessary to support the authorization of new gene therapies?
- What are the realities of bringing advanced therapeutics (stem cells, gene therapy, immune-oncology) to the patient bedside?

Dr Marc Turner, Medical Director, SNBTS
Dr Magda Papadaki, Head of Manufacturing Innovation, The Association of the British Pharmaceutical Industry

11:45 Industrialization of the cell and gene therapy industry

- At what stage do cell therapy companies typically start to consider up-scaling manufacturing and what upstream/downstream issues can that create?
- How the high price of gene therapies reflects the cost of preclinical development, manufacturing, distribution. How can these costs be brought down and what are the challenges for the standard reimbursement policies of governments, healthcare systems and insurance companies?

Dr David Sourdive, EVP Technical Operations, Cellectis
Dr Timothy Moore, EVP Technical Operations, Kite Pharma

12.30: EVENT PARTNER PRESENTATION: Identify barriers and opportunities in infrastructure supply chains

- Translational challenges of creating a supply chain for commercialization to a much broader market as well as passing typical drug regulatory body scrutiny.
- Cost and difficulties in establishing standardized quality assurance programs and reliable transport systems for the movement of patient cells from the clinic through the manufacturing facility and back.

12.45: Getting advanced therapies to frontline patient care. What are the challenges associated with market access, pricing & reimbursement?

- What are the unique regulatory and reimbursement challenges for ATMPs?

Dr Nick Crabb, Programme Director, Scientific Affairs, NICE
Tay Salimullah, Global Pricing & Market Access Director, Cell & Gene Therapies, Novartis Pharma AG

13.15: Lunch & Networking

14.15:Company Presentations

16.15: (8 x early stage | 8 x late stage)

- Presentations from a range of publicly listed and private life science companies looking to raise finance and/or find partners. Biotechs include: Arthrogen, Synpromics

16.15: Refreshments & Networking

16.45 Closing Panel: Forecasts and Predictions

- What will the challenges for investors to assess profitable and revolutionary medicines in these research areas?

The gene therapy industry is predicted to achieve revenues of $204million in 2020 and the immuno-oncology market up to $34billion by 2024.
- How are earlier stage investors helping develop and build the next wave of advanced therapies companies?
- The evolving and dynamic role that pharma and corporate venture plays in early stage finance and industry collaborations
- The challenges and opportunities in assessing profitable and revolutionary medicines and achieving predicted revenues

Dr Markus Goebel, Managing Director, Novartis Venture Fund
Dr Hakan Goker, Senior Investment Director, Merck Ventures
Robin Davison, Investment Analyst, New Science Global
Simon Goldman, Investment Manager – UCL Technology Fund, Albion Ventures

17.30: Networking Drinks Reception

With thanks to our hosts CMS

Register your place now at: www.advancedtherapiesinvestment.com
TIMING
Scheduling alongside ISCT 2017 ensures access to more of the most active pharma and biotech companies as well as the most exciting early stage biotech’s and academic spinouts who will already be in London.

QUALITY
The Phacilitate & Biotech and Money partnership will ensure a world class audience of global leaders in cell, gene and immunotherapy alongside more relevant investors (50+) than any other EU event.

SCOPE
The associated industry report will be the definitive sector analysis informing the investor and partnering community. Independent, in-depth and aimed at demystifying the advanced therapy landscape, it will be distributed to an audience of industry stakeholders.

PURPOSE
Unlike other “Industry Overview” style reports, we will provide the investment/partnering community with independent, expert, detailed and actionable commentary and analysis to ensure the most effective investment decision making.

DELEGATE PRICING MATRIX

<table>
<thead>
<tr>
<th>Ticket Name</th>
<th>Early Bird (Ends 17/03/2017)</th>
<th>Standard Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharma / Biotech</td>
<td>£1,100</td>
<td>£1,250</td>
</tr>
<tr>
<td>Tools / Service Provider</td>
<td>£1,850</td>
<td>£1,850</td>
</tr>
<tr>
<td>Academic / Government / Not-for-profit</td>
<td>£700</td>
<td>£750</td>
</tr>
<tr>
<td>Investor</td>
<td>FREE</td>
<td>FREE</td>
</tr>
</tbody>
</table>

Go to www.advancedtherapiesinvestment.com to register your place now! If you are having any difficulties, please contact Paul Hemmings on +44 (0)20 7384 7916 or paul.hemmings@clarionevents.com.

SPONSORSHIP OPPORTUNITIES

HEADLINE SPONSOR
GOLD SPONSOR
SILVER SPONSOR
COMPANY PRESENTATION SPONSOR
PRIVATE LUNCH SPONSOR
DRINKS RECEPTION SPONSOR
BESPOKE MEETING PACKAGE (ADD-ON)
EXECUTIVE INTERVIEW IN THE INVESTMENT REPORT
FULL PAGE ADVERT IN THE INVESTMENT REPORT

Learn how you can be a part of it from Peter Harkness on +44 (0)207 384 8027 or at peter.harkness@phacilitate.co.uk.